SignalXSignalX

RYTM RHYTHM PHARMACEUTICALS, INC.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
RHYTHM PHARMACEUTICALS, INC. Overview

RHYTHM PHARMACEUTICALS, INC. (RYTM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk from July 2025 $188.7M follow-on public offering; impact on capital structure and dilution risk increased
  • • RIFA royalty burden update: tiered royalties 11.5%-2.5% on net revenues up to $300M+, $34.9M paid through Sept 2025, limits cash flow flexibility
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$51M

Net Income

-$53M

Operating Margin

-102.6%

Net Margin

-103.1%

ROE

-35.5%

Total Assets

$507M

Source: XBRL data from RHYTHM PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on RHYTHM PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.